Back Other Health News Other Health News Topics Other STDs

CDC Releases Updated Sexually Transmitted Disease Treatment Guidelines

In June the U.S. Centers for Disease Control and Prevention (CDC) published updates guidelines for the treatment of sexually transmitted diseases (STDs). The guidelines include information on more than 2 dozen different sexually transmitted infections, as well as STD complications such as pelvic inflammatory disease and cervical and anal cancer.


April Is Sexually Transmitted Disease Awareness Month

April is STD Awareness Month in the U.S., an opportunity to promote education and raise awareness about sexually transmitted infections and to encourage people to get tested. Half of the estimated 20 million STDs that occur in the U.S. each year are among young people, and this year's STD Awareness Month effort focuses on this population.


New Antibiotic Regimens Shown Effective Against Drug-resistant Gonorrhea

A pair of antibiotic regimens using the existing drugs gentamicin or gemifloxacin plus azithromycin work against resistant gonorrhea, but come with side effects, CDC and NIH researchers reported at the 20th Meeting of the International Society for Sexually Transmitted Diseases Research this week in Vienna.


Latest CDC Sexually Transmitted Disease Report Shows Gonorrhea Stable, Syphilis Rising

The number of cases of chlamydia declined slightly from 2012 to 2013, while cases of gonorrhea remained nearly stable and syphilis increased by 10%, according the latest Centers for Disease Control and Prevention (CDC) annual STD surveillance report. These broad trends, however, mask some notable differences between population groups, including high STD rates among gay men.


Drug Resistant Gonorrhea Makes its Way into North America

The first documented failure of oral treatment for gonorrhea in North America has been reported in Toronto. The article, Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefexime in Toronto, Canada, published in the January 9, 2013, Journal of the American Medical Association, provides support for growing concern surrounding the second most prevalent bacterial sexually transmitted infection in the world.

IDWeek 2014: Syphilis Cases Increase Among Men with HIV Despite Risk Reduction Counseling

There has been a substantial increase in the number of syphilis cases among men living with HIV -- particularly men who have sex with men (MSM) -- despite systematic risk reduction counseling in this population since 2008, according to a study conducted at a clinic in rural Pennsylvania presented at IDWeek 2014 earlier this month.


CDC Recommendation: Dual Treatment to Curb Tide of Drug-Resistant Gonorrhea

Increasing fears about the emergence of antibiotic resistant gonorrhea in the U.S. have prompted new treatment and surveillance recommendations from the Centers for Disease Control and Prevention (CDC). Gail Bolan, director of the agency's Division of STD Prevention, called the move "a critical pre-emptive strike to preserve the last effective treatment option." alt

Chlamydia Widespread in U.S., Task Force Recommends Screening for Young Women

Chlamydia -- the most commonly reported sexually transmitted infection in the U.S. -- had an overall prevalence of 1.7% among people age 14 to 39 in the latest NHANES survey, but this rose to 4.7% among sexually active young women. Updated guidelines from the U.S. Preventive Services Task Force recommend regular chlamydia and gonorrhea screening for sexually active women age 24 and younger, and for older women at increased risk for infection, but state that there is not enough evidence to make a similar recommendation for men.


WHO Warns of Global Threat of Drug-resistant Gonorrhea

Multidrug-resistant gonorrhea is a growing concern worldwide and millions of people may be at risk of running out of treatment options unless urgent action is taken, according to an alert issued this week by the World Health Organization (WHO).alt

ICAAC 2014: Delafloxacin Shows Promise as a Single-dose Treatment for Gonorrhea

A new antibiotic, delafloxacin, demonstrated potent activity against gonorrhea -- including drug-resistant strains -- in a laboratory study, and its pharmacokinetics suggest that single-dose oral treatment will be feasible, according to research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.


Researchers Report Setbacks on Herpes Simplex Vaccine and Treatment

An experimental herpes simplex virus (HSV) vaccine partially protected women against infection with HSV type 1 but not type 2, according to a recent report in the New England Journal of Medicine. Another recent study found that antiviral treatment with acyclovir (Zovirax) or valacyclovir (Valtrex) did not prevent periodic HSV-2 reactivation and viral shedding.alt

STD Prevention Conference: Drug-resistant Gonorrhea Rates Plummet in U.S.

Preliminary results announced at the U.S. 2014 STD Prevention Conference last week in Atlanta have shown that the proportion of cases of gonorrhea that are drug-resistant has fallen since 2011, with a sharp decline between 2012 and 2013. The fall is particularly marked among gay and other men who have sex with men (MSM), who had had the highest rates of drug-resistant gonorrhea.

Gonorrhea May Become Untreatable Due to Resistance, Experts Warn

Neisseria gonorrhoeae,the bacteria that cause gonorrhea, are becoming increasingly resistant to existing drugs and more difficult to treat in the U.S., public health experts warn in the February 9, 2012, New England Journal of Medicine.


Coalition Calls for Wider Use of Sexual Health Care Services in U.S.

The National Coalition for Sexual Health -- comprised of nearly 40 organizations focused on HIV, sexually transmitted diseases, and other aspects of sexual health -- last week issued a call-to-action and announced new resources aimed at improving access to and acceptance of sexual health services, which are now more readily available under the Affordable Care Act (ACA).


STD Report Shows Small Rise Overall, Higher Rates for People of Color, Young Gay Men

Reported cases of gonorrhea rose slightly and syphilis declined somewhat during 2010, but the syphilis rate among young black men has increased dramatically over the past 5 years, largely driven by increases among men who have sex with men (MSM), according to the latest sexually transmitted disease (STD) surveillance report from the Centers for Disease Control and Prevention (CDC).alt

Helicase Inhibitor Pritelivir Shows Promise Against Genital Herpes

Pritelivir, a helicase inhibitor that interferes with viral replication, reduced the rate of herpes simplex virus type 2 (HSV-2) genital shedding, which has the potential to reduce sexual transmission, according to a small study described in the January 16, 2014, New England Journal of Medicine.


Sexual Partners Should Get Expedited Treatment for Chlamydia and Gonorrhea

Male sexual partners of women diagnosed with chlamydia or gonorrhea should be prescribed antibiotics in an effort to prevent passing infections back and forth, according to new guidelines from the American College of Obstetricians and Gynecologists (ACOG).alt

CDC STD Report Shows Rise in Gonorhea, Syphilis

The U.S. Centers for Disease Control and Prevention (CDC) this week released its annual sexually transmitted disease (STD) surveillance report on chlamydia, gonorrhea, and syphilis, showing that the latter two infections have increased by 4% and 11%, respectively, with the rise in syphilis occurring primarily among gay and bisexual men.


Genital Herpes Virus Can Spread Despite Lack of Symptoms

People without genital sores or other symptoms can still shed and transmit herpes simplex virus type 2 (HSV-2) during sex, according to a recent U.S. study. alt

ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding

An experimental immune-modulating vaccine significantly reduced shedding of herpes simplex virus type 2 (HSV-2) in people with recurrent genital herpes, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver. The vaccine appeared safe and well-tolerated.


Oral Tenofovir Does Not Reduce Herpes Virus Shedding

HIV positive people who took tenofovir (Viread, also in the Truvada and Atripla combination pills) as part of their antiretroviral regimen were no less likely to shed herpes simplex virus 1 or 2 (HSV-1 or HSV-2) than individuals using non-tenofovir regimens, according to research described in the January 14, 2011, issue of AIDS. These findings are notable because a recent microbicide study found that a tenofovir gel reduced the likelihood of HSV-2 infection.